S&P 500   4,555.58 (+0.11%)
DOW   35,715.58 (+0.80%)
QQQ   388.88 (-0.24%)
AAPL   189.24 (-0.07%)
MSFT   378.76 (-0.02%)
META   329.93 (-0.68%)
GOOGL   134.16 (-0.61%)
AMZN   145.90 (-0.29%)
TSLA   241.13 (-1.23%)
NVDA   476.91 (-0.93%)
NIO   7.21 (+0.42%)
BABA   74.23 (-0.59%)
AMD   121.93 (-1.55%)
T   16.40 (+0.61%)
F   10.47 (-1.13%)
MU   75.83 (-1.12%)
CGC   0.55 (-1.89%)
GE   119.06 (+0.17%)
DIS   92.99 (+0.53%)
AMC   7.00 (-2.37%)
PFE   30.05 (-0.10%)
PYPL   57.46 (-0.88%)
XOM   104.10 (+1.72%)
S&P 500   4,555.58 (+0.11%)
DOW   35,715.58 (+0.80%)
QQQ   388.88 (-0.24%)
AAPL   189.24 (-0.07%)
MSFT   378.76 (-0.02%)
META   329.93 (-0.68%)
GOOGL   134.16 (-0.61%)
AMZN   145.90 (-0.29%)
TSLA   241.13 (-1.23%)
NVDA   476.91 (-0.93%)
NIO   7.21 (+0.42%)
BABA   74.23 (-0.59%)
AMD   121.93 (-1.55%)
T   16.40 (+0.61%)
F   10.47 (-1.13%)
MU   75.83 (-1.12%)
CGC   0.55 (-1.89%)
GE   119.06 (+0.17%)
DIS   92.99 (+0.53%)
AMC   7.00 (-2.37%)
PFE   30.05 (-0.10%)
PYPL   57.46 (-0.88%)
XOM   104.10 (+1.72%)
S&P 500   4,555.58 (+0.11%)
DOW   35,715.58 (+0.80%)
QQQ   388.88 (-0.24%)
AAPL   189.24 (-0.07%)
MSFT   378.76 (-0.02%)
META   329.93 (-0.68%)
GOOGL   134.16 (-0.61%)
AMZN   145.90 (-0.29%)
TSLA   241.13 (-1.23%)
NVDA   476.91 (-0.93%)
NIO   7.21 (+0.42%)
BABA   74.23 (-0.59%)
AMD   121.93 (-1.55%)
T   16.40 (+0.61%)
F   10.47 (-1.13%)
MU   75.83 (-1.12%)
CGC   0.55 (-1.89%)
GE   119.06 (+0.17%)
DIS   92.99 (+0.53%)
AMC   7.00 (-2.37%)
PFE   30.05 (-0.10%)
PYPL   57.46 (-0.88%)
XOM   104.10 (+1.72%)
S&P 500   4,555.58 (+0.11%)
DOW   35,715.58 (+0.80%)
QQQ   388.88 (-0.24%)
AAPL   189.24 (-0.07%)
MSFT   378.76 (-0.02%)
META   329.93 (-0.68%)
GOOGL   134.16 (-0.61%)
AMZN   145.90 (-0.29%)
TSLA   241.13 (-1.23%)
NVDA   476.91 (-0.93%)
NIO   7.21 (+0.42%)
BABA   74.23 (-0.59%)
AMD   121.93 (-1.55%)
T   16.40 (+0.61%)
F   10.47 (-1.13%)
MU   75.83 (-1.12%)
CGC   0.55 (-1.89%)
GE   119.06 (+0.17%)
DIS   92.99 (+0.53%)
AMC   7.00 (-2.37%)
PFE   30.05 (-0.10%)
PYPL   57.46 (-0.88%)
XOM   104.10 (+1.72%)

Syndax Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SNDX)

$16.54
+0.24 (+1.47%)
(As of 09:46 AM ET)
Compare
Today's Range
$16.47
$16.77
50-Day Range
$11.39
$16.30
52-Week Range
$11.22
$29.86
Volume
69,770 shs
Average Volume
1.08 million shs
Market Capitalization
$1.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.09

Syndax Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
115.3% Upside
$35.09 Price Target
Short Interest
Bearish
15.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.63mentions of Syndax Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.97) to ($3.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

528th out of 949 stocks

Pharmaceutical Preparations Industry

258th out of 445 stocks


SNDX stock logo

About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

SNDX Stock Price History

SNDX Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Analyst Ratings for Syndax Pharmaceuticals
See More Headlines
Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNDX
Employees
107
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.09
High Stock Price Target
$43.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+115.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-149,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$139.71 million
Book Value
$5.16 per share

Miscellaneous

Free Float
66,368,000
Market Cap
$1.14 billion
Optionable
Optionable
Beta
1.04
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Michael A. Metzger M.B.A.Mr. Michael A. Metzger M.B.A. (Age 52)
    CEO & Director
    Comp: $1.05M
  • Mr. Keith Alan Goldan CPA (Age 52)
    CFO, Treasurer & Chief Accounting Officer
    Comp: $649.07k
  • Mr. Luke J. Albrecht (Age 43)
    Senior VP, General Counsel & Secretary
    Comp: $605.82k
  • Dr. Catherine Madigan M.D. (Age 51)
    Chief Medical Officer
    Comp: $764.41k
  • Mr. Steve M. Sabus (Age 57)
    Chief Commercial Officer
    Comp: $523.44k
  • Dr. Peter Ordentlich B.Sc. (Age 54)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Dr. Richard A. Heyman Ph.D. (Age 66)
    Co-Founder
  • Dr. Ronald M. Evans Ph.D. (Age 74)
    Co-Founder, Advisor and Chair of Scientific Advisory Board
  • Dr. Michael Downes Ph.D.
    Co-Founder
  • Sharon Klahre
    Vice President of Investor Relations & Communications














SNDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Syndax Pharmaceuticals stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SNDX shares.
View SNDX analyst ratings
or view top-rated stocks.

What is Syndax Pharmaceuticals' stock price target for 2024?

10 Wall Street analysts have issued 12-month price objectives for Syndax Pharmaceuticals' shares. Their SNDX share price targets range from $28.00 to $43.00. On average, they anticipate the company's share price to reach $35.09 in the next year. This suggests a possible upside of 115.3% from the stock's current price.
View analysts price targets for SNDX
or view top-rated stocks among Wall Street analysts.

How have SNDX shares performed in 2023?

Syndax Pharmaceuticals' stock was trading at $25.45 at the beginning of the year. Since then, SNDX shares have decreased by 36.0% and is now trading at $16.30.
View the best growth stocks for 2023 here
.

When is Syndax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our SNDX earnings forecast
.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) issued its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.07.

What ETFs hold Syndax Pharmaceuticals' stock?

ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Simplify Health Care ETF (PINK).

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Who are Syndax Pharmaceuticals' major shareholders?

Syndax Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Avidity Partners Management LP (4.05%), Jennison Associates LLC (3.38%), Adage Capital Partners GP L.L.C. (1.44%), Group One Trading L.P. (0.00%), Northern Trust Corp (0.91%) and Charles Schwab Investment Management Inc. (0.73%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Keith A Goldan, Keith Katkin, Michael A Metzger, Michael L Meyers, Peter Ordentlich, Pierre Legault and William Meury.
View institutional ownership trends
.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SNDX) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -